SCHEMBL2238447

SCHEMBL2238447

CC(=O)OCC1OC(n2ccc(N)nc2=O)C(OC(C)=O)C1OC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
THRB P10828 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HIF1A Q16665 1/20 0.53
ALDH1A1 P00352 2/20 0.52
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MTOR P42345 1/20 0.51
MDM2 Q00987 1/20 0.51
NCOA1 Q15788 1/20 0.51
NCOA3 Q9Y6Q9 1/20 0.51
CA1 P00915 6/20 0.47
CA2 P00918 6/20 0.47
CA9 Q16790 6/20 0.47
CA12 O43570 5/20 0.47
CA14 Q9ULX7 5/20 0.47
TSHR P16473 1/20 0.46
PRKCA P17252 1/20 0.46
AKT1 P31749 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10813233 1.00 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL9068649 1.00 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL6536598 1.00 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Hydrochloric Acid SCHEMBL4977129 0.99 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Hydrochloric Acid SCHEMBL4977138 0.99 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Hydrochloric Acid SCHEMBL7932700 0.99 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10431963 0.93 LMNA (0.50) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL11793030 0.92 LMNA (0.57) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL11807658 0.91 LMNA (0.48) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10589686 0.91 LMNA (0.48) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528930-B1 4'-AZIDO-NUCLEOSIDES AS ANTI-HCV COMPOUNDS HOFFMANN LA ROCHE (CH) 2013-10-30 EP disclosed
EP-2528930-A1 4 ' - AZIDO - NUCLEOSIDES AS ANTI - HCV COMPUNDS F. Hoffmann-La Roche AG (CH) 2012-12-05 EP disclosed
WO-2011092158-A1 4 ' - AZIDO - NUCLEOSIDES AS ANTI - HCV COMPUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-08-04 WO disclosed
EP-1565481-B1 ANTIVIRAL NUCLEOSIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-08-09 EP disclosed
EP-1565481-A1 ANTIVIRAL NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-24 EP disclosed
US-6846810-B2 Hepatitits virus ROCHE PALO ALTO LLC (US) 2005-01-25 US disclosed
US-20040121980-A1 Antiviral nucleoside derivatives ROCHE PALO ALTO LLC 2004-06-24 US disclosed
WO-2004046159-A1 ANTIVIRAL NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121980-A1 Antiviral nucleoside derivatives SLC29A1, SAMHD1, NUDT1 LMNA 1974/4885THRB 4178/4885SMN1; SMN2 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.